Coronavirus vaccine - Theralase Technologies
Alternative Names: Photo Dynamic Compound Inactivated SARS-CoV-2 Vaccine - Theralase TechnologiesLatest Information Update: 16 May 2022
At a glance
- Originator Theralase Technologies; University of Manitoba
- Developer Public Health Agency of Canada; Theralase Technologies; University of Manitoba
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
- 29 Apr 2022 Theralase plans a preclinical trial for COVID-2019 infections in 2Q 2022
- 09 Apr 2021 Theralase Technologies executes a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health Agency of Canada (PHAC) for the research and development of a Canadian-based SARS-CoV-2 (COVID-19) vaccine
- 09 Apr 2021 Early research in COVID-2019 infections (Prevention) in Canada, prior to April 2021